EGFR and neoplasm: Indeed, studies on different components of the tumor microenvironment led to the development of several targeted treatments, such as anti-VEGF, anti-EGFR, or, more recently, anti-PD-1, PD-L1, or CTLA4 antibodies, that considerably improved the prognosis of cancer patients.